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ABSTRACT
The over-accumulation of glycogen appears as a hallmark in various glycogen storage diseases 
(GSDs), including Pompe, Cori, Andersen and Lafora disease. Accumulating evidence suggests 
that suppression of glycogen accumulation represents a potential therapeutic approach for 
treating these GSDs. Using a fluorescence polarization assay designed to screen for inhibitors of 
the key glycogen synthetic enzyme, glycogen synthase (GS), we identified a substituted 
imidazole, (rac)-2-methoxy-4-(1-(2-(1-methylpyrrolidin-2-yl)ethyl)-4-phenyl-1H-imidazol-5-
yl)phenol (H23), as a first-in-class inhibitor for yeast glycogen synthase 2 (yGsy2p). Data from 
X-ray crystallography at 2.85 Å, as well as kinetic data, revealed that H23 bound within the
UDP-glucose binding pocket of yGsy2p. The high conservation of residues between human and 
yeast GS in direct contact with H23 informed the development of around 500 H23 analogs. 
These analogs produced a structure-activity relationship (SAR) profile that led to the 
identification of a substituted pyrazole, 4-(4-(4-hydroxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-
5-yl)pyrogallol, with 300-fold improved potency against human GS. These substituted pyrazoles
possess a promising scaffold for drug development efforts targeting GS activity in GSDs 
associated with excess glycogen accumulation.
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Glycogen is a branched polymer of glucose, composed of chains thirteen residues long on 
average, arranged in layers to form a molecule of up 107 daltons, corresponding to 55,000 
glucose units. The biosynthesis of glycogen is a highly conserved, complex and coordinated 
process that involves two key events. Glycogen synthase (GS) lengthens linear chains through 
the progressive addition of -1,4-linked glucose residues to the non-reducing end of the polymer, 
and glycogen-branching enzyme (GBE) catalyzes the intramolecular transfer of seven glucose 
residues from the end of a linear chain to a C-6 hydroxyl group to produce -1,6 branch points 
for further elongation1,2,3,4. 
GS is the rate-limiting enzyme for glycogen biosynthesis5. Higher eukaryotes have two isoforms, 
GYS1 and GYS26,7, that share approximately 70% sequence identity at the amino acid level and 
display the greatest variation within the N- and C-terminal sequence extensions where regulatory 
sites are located. The two GS isoenzymes are differentially expressed: GYS2 is exclusively 
expressed in the liver, while expression of GYS1 is highest in skeletal muscle but is also 
expressed in most other tissues. These two principal storage tissues for glycogen serve distinct 
physiological roles. Glycogen in the liver plays an essential, regulatory role in glucose 
homoeostasis, but glycogen in other tissues acts as an intracellular energy reserve such as during 
muscle contraction8. Similar to higher eukaryotes, Saccharomyces cerevisiae has two genes 
encoding GS, GSY1 and GSY2, with Gsy2p as the predominant isoform9. GS undergoes 
activation allosterically through glucose-6-phosphate (G6P) binding and inactivation by 
phosphorylation at a number of sites through the action of multiple protein kinases, including 
glycogen synthase kinase-3 (GSK-3) in mammals10,11. After transport into cells, glucose 
undergoes phosphorylation to G6P and enters one of several metabolic pathways. Increased 
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levels of intracellular G6P stimulates GS activity that in turn drives the incorporation of glucose 
into glycogen in a feed-forward mechanism12. The dephosphorylation of GS is mediated by 
forms of type 1 protein phosphatase (PP1), the catalytic subunit of which is held in close 
proximity to the glycogen granule and GS by a family of glycogen targeting subunits, including 
protein-targeting-to-glycogen (PTG), an indirect activator of GS13. 
Glycogen metabolism constitutes a key pathway in living cells that regulates systemic carbon or 
energy allocation14. A number of diseases are associated with abnormal glycogen metabolism 
including type 2 diabetes (T2D) and glycogen storage diseases (GSDs)15,16,17. Defects in 
enzymes directly involved in either glycogen synthesis or degradation18 are the basis for more 
than 12 different GSDs, and glycogen over-accumulation is characteristic of most GSDs. In 
Pompe disease (GSD2), a deficiency of the enzyme, acid--glucosidase (GAA), leads to 
lysosomal glycogen accumulation in many tissues including skeletal, cardiac, and smooth 
muscle19. In Cori disease (GSD3) and Andersen disease (GSD4), defects in the glycogen 
debranching enzyme (AGL) and glycogen branching enzyme (GBE1), respectively, result in the 
accumulation of glycogen with abnormal structure20,21. Lafora disease is a fatal progressive 
myoclonus epilepsy accompanied by neurodegeneration for which the presence of abnormal 
glycogen inclusions known as Lafora bodies22 are the hallmark. Lafora bodies consist of poorly 
branched, hyperphosphorylated, and insoluble forms of glycogen that occur in neuronal, muscle 
and other tissues23,24,25. Notably, impaired glycogen metabolism and consequent glycogen 
accumulation was also found to be pathological for β-cell dysfunction in T2D16,17.   
A common finding with excess glycogen accumulation is an association with impaired 
autophagy and dysregulated mitochondrial metabolism. These derangements often lead to cell 
death and early-onset lethal, disease progression in GSD-affected patients16,26,27. Currently, there 
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are no effective treatments for GSDs that ameliorate all cellular and organ dysfunction. For 
example, in Pompe disease, the administration of a genetically engineered enzyme (i.e., Enzyme 
Replacement Therapy, ERT) that rescues the defective GAA in peripheral tissues fails to reverse 
the neurological defects. Partial suppression of glycogen synthesis through inhibition of GS 
activity represents an alternative, potentially effective strategy for treating various types of GSDs 
where ERT may not provide a complete solution. For instance, mouse models of Lafora disease 
that lack either of the causative genes, EPM2A or EPM2B, recapitulate aspects of the patient 
phenotype, in that they accumulate polyglucosan bodies and misfolded proteins, display 
increased endoplasmic reticulum stress, and show signs of neurodegeneration23,27. Such animal 
models provided a venue for disrupting either PTG or GYS1 in these EPM2A(-/-) and EPM2B(-/-) 
knock-out mice as a mechanism for diminishing glycogen accumulation, Lafora body formation 
and the associated neurological and epileptic symptoms27,28,29,30. Inhibition of GS activity via 
suppression of mTOR signaling also increases the effectiveness of treatments for Pompe disease 
in conjunction with ERT31. Moreover, a recent report has shown that GYS2 inhibition with 
RNAi prevents liver injury in mouse models of GSDs32. Although human clinical characteristics 
may vary from animal phenotypes, the availability of mouse models and the appearance of 
promising therapeutic approaches suggest the feasibility of using small-molecule interventions to 
treat GSDs. We now report efforts to develop small-molecule inhibitors of human GS based on a 
multicomponent study involving high-throughput screening (HTS), X-ray crystallography and 
extensive SAR development work that led to substituted pyrazoles with low micromolar, 
inhibitory IC50 values against human glycogen synthase 1 (hGYS1).  
RESULTS
Development of fluorescence polarization assay for HTS
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The standard radiochemical assay for GS activity utilizes a time-consuming 14C-glucose 
incorporation assay (i.e., UDP-[U-14C]glucose and glycogen(n) affords [14C]glycogen(n+1) and 
UDP) that involves appropriate safety measures for handling radioisotopes as well as multiple 
transfer and washing steps to remove residual substrates33. The combination of laboratory effort, 
cost, safety and waste disposal favored the development of a fluorescence polarization (FP) assay 
for HTS as a sensitive, inexpensive, and rapid alternative34. We reserved the classical 
radiochemical assay for subsequent studies to confirm the hits emerging from the FP assay. An 
FP assay utilizes a fluorescently-labeled tracer molecule that binds to GS to form a slower 
rotating complex than fluorophore alone and that leads to enhanced polarization of the emitted 
light. Incubation of the GS-fluorophore complex with small-molecules that displace the 
fluorescent tracer produces greater rotational motion of fluorophore than that of the GS-
fluorophore complex and causes relative depolarization of the emitted light. Using this assay 
system as a vehicle for HTS, we identified small-molecules that reduce the fluorescence 
polarization signal as GS-interacting agents. 
The development of any FP assay involves the design and synthesis of a functional, fluorescent 
probe. Although G6P is a well-known, allosteric activator of GS, the regioselective modification 
of similarly reactive hydroxyl groups in G6P presented an unwelcome challenge. Because 
glucosamine-6-phosphate (GlcN6P) also activated GS35 and has a single, reactive amine group, 
its selection as a platform on which to incorporate a fluorophore was an attractive alternative to 
G6P. Using the 14C-glucose incorporation assay, we confirmed that either G6P or GlcN6P 
activated hGYS1 with AC50 values of 1.6 0.1 mM or 5.9 0.1 mM, respectively  ±   ±  
(Supplemental Figure 1A). With direct evidence in hand that GlcN6P activated hGS, we 
synthesized a fluorophore-modified GlcN6P (aka GlcN6P-fluorescein-5-Ex) using GlcN6P and 
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the N-hydroxysuccinimidyl ester of fluorescein-5-Ex (Figure 1A), purified the fluorophore by 
high-performance liquid chromatography (HPLC) and confirmed the expected molecular mass 
by mass spectrometry in which it displayed a M+H+ peak at m/z 735.1267 consistent with 
[C31H31N2O15PS + H]+ with calculated exact mass within acceptable limits (i.e., calculated m/z 
735.1256) (Supplemental Figure 1B).
We examined the binding of the fluorophore, GlcN6P-fluorescein-5-Ex, to GS by adding the 
tracer to varying concentrations of yGsy2p to generate a saturation binding curve and calculate a 
dissociation constant of 7.6 0.7 μM (Figure 1B). Furthermore, a competitive displacement by  ±  
G6P (Kd  70.9 3.6 µM) demonstrated that the tracer molecule bound to the G6P allosteric =  ±  
site (Figure 1C). For comparison, we determined yGsy2p activation by G6P using the standard 
14C-glucose incorporation assay which yielded an AC50 of 98.1 3.1 µM (Supplemental  ±  
Figure 1C). We also tested the binding of GlcN6P-fluorescein-5-Ex and displacement by G6P 
using hGYS1. While the GlcN6P-coupled fluorophore and the fluorophore alone bound to 
hGYS1, G6P was unable to displace either compound, a finding that suggested nonspecific 
binding of the fluorophore to hGYS1. This reason, combined with the fact that production of 
human GYS1 in insect cells results in a heavily phosphorylated enzyme that requires very high 
concentrations of G6P for activity measurements, makes the full-length recombinant human 
enzyme unsuitable for an assay designed to displace G6P. However, since the fluorescent probe 
could be fully displaced from yGsy2p through competition with G6P, we used yGsy2p and not 
hGYS1 for HTS. The high conservation of residues within the G6P allosteric site, the active site, 
and overall protein sequence identity (~55%) between yGsy2p and hGYS1 further supported the 
decision to use the yeast enzyme as a screening surrogate for the human enzyme (Supplemental 
Figure 2). The robustness of the FP assay for HTS was assessed by determining the Z′-factor, a 
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parameter reflective of both the signal dynamic range and data variability36. While the ideal Z′-
factor is 1, a Z′-factor between 0.5 and 1 is considered excellent and suitable for screening 
assays. The FP values for the positive controls (maximal binding, without G6P) and negative 
controls (fully displaced tracer, with G6P) were 109.23 ± 1.97 and 26.48 ± 1.93 (mean ± SD) 
from the 384-wells, respectively. The Z′-factor for this assay was determined as 0.86, indicating 
that this assay is well suited for HTS (Figure 1D).  
 
Figure 1. Development of fluorescence polarization assay for HTS. (A) 2-(6-Hydroxy-3-oxo-
3H-xanthen-9-yl)-5-(2-((3-oxo-3-(((2R,3R,4R,5S,6R)-2,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)propyl)thio)acetamido)benzoic acid (β-anomer 
of GlcN6P-fluorescein-5-Ex). (B) Saturation binding isotherm for GlcN6P-fluorescein-5-Ex 
Page 8 of 48
ACS Paragon Plus Environment






























































binding to yGsy2p. The binding affinity was determined by adding GlcN6P-fluorescein-5-Ex to 
a final concentration of 20 nM in the presence of varying yGsy2p concentrations (0 to 50 µM). 
Kd= 7.6 0.7 µM. Averages of triplicate assays ± SEM are shown. (C) Displacement of  ±  
GlcN6P-fluorescein-5-Ex binding to yGsy2p by G6P. A mixture of yGsy2p and GlcN6P-
fluorescein-Ex was added to various G6P concentrations (0.68 µM to 40 mM). Kd= 70.9 3.6  ±  
µM. Averages of triplicate assays ± SEM are shown. (D) Z′-factor determination: fluorescence 
polarization values of the bound (-G6P), and the free (+2 mM G6P) GlcN6P-fluorescein-5-Ex 
are shown, for the 16 rows with each row containing 12 columns of either the bound or free state. 
The graphs depict a representative experiment from at least three independent experiments.  
Hits identification and validation 
We used the aforementioned FP displacement assay to screen the 50K ChemBridge Diversity 
library at a final assay concentration of 10 μM against the yGsy2p enzyme. The HTS was 
adapted to the 384-well plate format using three columns for the DMSO negative controls and 
one column for unlabeled G6P as the positive control, resulting in a total of 157 screening plates 
(Supplemental Table 1 and 2). We used a Z’-score threshold of -1, corresponding to a 
separation of 3 standard deviations between μc (means of the control DMSO signal) and μs 
(means of the library sample signal) as a signal cutoff (Supplemental Table 2). These standards 
produced 117 hits and an overall 0.23% hit rate. Initial stock availability led to re-purchasing of 
110 compounds (designated H1-H110) from ChemBridge and validation of their activity using 
the standard 14C-glucose incorporation assay at 100 μM concentration. This approach validated 
16 hits with greater than 40% inhibition of yGsy2p activity (Figure 2A). 
Since the yeast yGsy2p enzyme was used as a surrogate for the human hGYS1 enzyme, we next 
examined if the 16 validated compounds were also active as inhibitors of hGYS1 activity. To 
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accomplish this necessary confirmation, we redesigned the hGYS1 construct to create a 
constitutively active enzyme through deletion of the C-terminal phosphorylation domain 
(residues 635-737) and through the substitution of the two N-terminal phosphorylation sites 
(Ser8, Ser11) with Asn residues (designated hGYS1634S8,11N) (Figure 2B). Purification of 
this truncated form of GS in significant quantity led to an enzyme that exhibited an activation 
state of ~0.2, a ratio of GS activity in the absence over the presence of G6P as an index of the 
phosphorylation state of the enzyme37. Unlike the heavily phosphorylated, full-length enzyme 
produced in insect cells that had an activation state of <0.0138, this truncated form of GS was 
well suited for validation assays designed to look for inhibitors because the enzyme was neither 
overly inhibited by phosphorylation nor rendered insensitive to the effects of G6P. At a test 
concentration of 100 μM, only 1 hit, namely a substituted imidazole, (rac)-2-methoxy-4-(1-(2-
(1-methylpyrrolidin-2-yl)ethyl)-4-phenyl-1H-imidazol-5-yl)phenol (H23), demonstrated greater 
than 20% inhibition using this truncated hGYS1 (Figure 2C and 2D). 
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Figure 2. Hits identification and validation. (A) In the FP assay, setting a Z’-score threshold of 
-1 gave 117 initial hits, out of which 110 (designated H1-H110) were re-purchased and tested. 
The blue column represents the percentage of fluorescence polarization signal to control. The 
hits were screened at 10 μM in single measurement. The orange column is the percentage of 
yGsy2p activity to control measured through 14C-glucose incorporation assay. The hits were 
tested at 100 μM. Averages of triplicate assays ± SEM are shown. (B) Schematic representation 
of yGsy2p and hGYS1 protein. Phosphorylation residues are shown in red. To generate 
hGYS1Δ634S8,11N mutant, hGSY1 was truncated at position 634 with mutations of Ser8/11 to 
Asn to eliminate potential phosphorylation sites. (C) Percentage of hGYS1Δ634S8,11N activity 
to control measured through 14C-glucose incorporation assay. The hits were tested at 100 μM. 
Averages of triplicate assays ± SEM are shown. (D) Screening triaging strategy. 
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Crystal structure of the H23-yGsy2p complex        
Although there are no mammalian GS crystal structures, the structures of two eukaryotic 
enzymes, namely yGsy2p from Saccharomyces cerevisiae10 and GS from Caenorhabditis 
elegans39 encouraged our undertaking crystallization experiments. As previously described, yeast 
Gsy2p existed as tetramer in the crystal structure, and each subunit contained two Rossmann-fold 
domains with the catalytic site in the interdomain cleft10. In the crystal packing environment in 
crystals of the activated form of GS, one subunit appeared 13.3º more closed than the other three 
“open” subunits40. We successfully determined the crystal structure of the H23-yGsy2p complex 
to a resolution of 2.85 Å (Table 1), and we observed H23 binding in three of the four subunits, 
all of which corresponded to the “open” domain positions (Figure 3B). The structure showed 
H23 bound within the active site of GS in a location that overlapped with the binding site for 
UDP-glucose (UDPG)40 (Figure 3C and 3D). Structural alignment of the R589/592A2·UDP 
complex to the WT·H23 complex using their Cα carbons generated an overall root mean square 
deviation (rmsd) of 0.36 Å, indicating a high degree of similarity. The binding of H23 to yGsy2p 
was mediated by hydrogen-bond formation between the phenolic hydroxyl group of H23 and the 
nitrogen backbone of Leu481; hydrophobic interactions of the 2-methoxyphenol sandwiched 
between Tyr492 and Phe480; van der Waals interactions of the benzene group with the side 
chains of Phe480 and Arg320; and additional van der Waals interactions of the N-
methylpyrrolidine moiety with Tyr492, Thr514, and Glu517 (Figure 3D).
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Figure 3. Crystal structure of the H23-yGsy2p complex (PDB: 6U77). (A) Chemical structure 
of H23. (B) Ribbon diagram representation of the crystal structure of H23-yGsy2p complex. 
H23 is represented by space-filling models in cyan, and binds to three subunits of yGsy2p which 
are colored differently. (C) The electron density for H23 prior to the inclusion of the ligand in 
refinement. The map shown is the original unbiased 2Fo-Fc map contoured at 1 standard 
deviation. (D) Stick representation of the superposed UDP (purple) and H23 (yellow) structures 
and their interactions with the surrounding amino acids.
Kinetic characterization of H23
In a study of the inhibitory potential for H23 against yeast and human GS using the standard 14C-
glucose incorporation assay, H23 exhibited IC50 values of 280 µM and 263 µM in the absence 
and presence, respectively, of G6P for yGsy2p (Figure 4A). The similarity in IC50 values 
indicated H23 was not in direct competition with G6P. Under subsaturating G6P concentrations, 
the IC50 values of H23 against either hGYS1634S8,11N or wild-type hGYS1 were 161 μM and 
875 µM, respectively (Figure 4B). Even though the presence or absence of G6P did not impact 
H23 potency, the activity state of the human GS enzyme had a five-fold effect on the binding of 
H23. 
To understand H23 mode of inhibition, we performed co-variation experiments by 
simultaneously varying the concentrations of UDPG at different fixed concentrations of H23 and 
fitting the kinetic data against the competitive, non-competitive and uncompetitive inhibition 
equations. For yGsy2p, the inhibition data with H23 was consistent with a competitive mode of 
inhibition with respect to varied UDPG, with Ki values of 370 M in the presence of G6P, and 
290 M in the absence of G6P. UDP displayed a similar competitive mode of inhibition with a 
Ki value of 350 M (Figure 4C). 
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Figure 4. Kinetic characterization of H23. (A) Inhibition of H23 to yGsy2p in the absence or 
presence of G6P. (B) Inhibition of H23 to hGYS1Δ634S8,11N and hGYS1 wild type. All IC50 
curves represent one of three experiments performed using triplicate measurements for each 
condition, with mean ± SEM shown. (C) Michaelis-Menten curves fit to the competitive 
inhibition equation for varied H23 versus UDPG. The values of goodness of fit (R2) are shown 
for all equations evaluated. H23 has a Ki of 370 ± 30 M in the presence of G6P and a Ki of 290 
± 20 M in the absence of G6P. UDP is used as a positive control for competitive inhibition 
against varied UDPG for yGsy2p, which displayed a Ki of 350 ± 10 M. The reported Ki values 
are the mean ± SEM from three independent experiments in duplicate.
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Development of structure-activity relationships for analogs of H23 toward hGYS1
The overall protein sequence alignment demonstrates 55% sequence identity between yGsy2p 
and hGYS1. Because the amino acids in the binding site for H23, including Arg320, Phe480, 
Leu481, Tyr492, and Glu517 in yGsy2p, are completely conserved across yeast and human 
species (Supplemental Figure 2), the structural information derived from H23-yGsy2p crystal 
structure provided a useful guide for structure-activity studies focused on hGYS1. We examined 
a total of 491 analogs that shared at least 50% structural similarity with H23, and we tested their 
activities against yGsy2p, hGYS1634S8,11N, and wild-type hGYS1 using the 14C-glucose 
incorporation assay. Our initial kinetic studies showed that a five-membered, heteroaryl (HA) 
core with a phenyl group at the A1 position, and a second, vicinal phenyl group were essential 
elements of H23 (Table 2). Consequently, analog development modified the HA core, A1 and 
substructures at R1-R7 positions shown in the structure in Table 2. In this study, all H23 analogs 
possessed one of the following HA cores: imidazole (designated as HA1), pyrrole (designated as 
HA2) or pyrazole (designated as HA3). Active compounds appeared in structures with any of 
these three cores, but the most potent compounds had a pyrazole (HA3) scaffold. Commercial 
libraries were the source of HA1 and HA2 compounds in Table 2, and a three-step synthesis 
provided the HA3 compounds as outlined in Scheme 1.
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Scheme 1. Synthesis of pyrazoles 11-30. Reagents and conditions: (a) (i) arylacetonitrile, 
BF3Et2O, HCl (gas), rt, 6-8 h, (ii) H+/H2O, 0.5-2 h; (b) (i) arylacetic acid, BF3Et2O, 80-90 0C, 2 
h, (ii) H2O; (c) (i) DMF, BF3Et2O, POCl3, 50-60 0C, 2 h, (ii) H2O; (d) (i) Ac2O, KOAc, reflux, 8 
h, (ii) H2SO4, EtOH, reflux, 0.5 h; (e) (i) (CF3CO)2O, pyridine, rt, 48-120 h, (ii) H2O; (f) 
N2H4H2O, reflux, 0.5-6 h.
A step-by-step program of modifying positions in H23 involved changes designed either to 
augment or diminish interactions with substituents in H23 and the adjoining residues in yGsy2p. 
Briefly, starting from the imidazole core (HA1), we determined that the R1 hydroxyl group that 
formed a hydrogen bond with the peptide nitrogen of Leu481 was essential to retain good 
inhibitory activity (i.e., compare H23 versus 1 in Table 2). The addition of an extra methylene 
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unit to the R7 chain eliminated inhibitory potential (4 versus 3). In a similar fashion, the most 
potent of the pyrrole HA2 compounds also had a hydroxyl group at R1 position (7 versus 9 or 10). 
Interestingly, substitution of a carboxyl group at R7 position improved the potency to hGYS1 by 
2-fold (IC50 values for H23 versus 7), a finding that suggested different conformational binding 
modes for H23 and 7 for hGYS1.
Because none of the analogs within the HA1 or HA2 series generated noteworthy improvements 
in potency, we turned to the pyrazole (HA3) series. Within the HA3 series, SAR studies 
demonstrated the importance of a hydrogen bond acceptor at the R1 position as displayed in the 
following order of potency: -OH > -NO2 > -CN > -F > -H > -Cl (i.e., 23 versus 27, 25, 19, 21 and 
15). When a chlorine is present at the R1 position, adding a second chlorine substituent at the R2 
position improved potency (12 versus 11 or 14 versus 13 or 17 versus 15). The most potent 
compounds in this series had a pyrrogallol group at the R4-6 positions, and the hydroxyl groups 
on this substituent conferred inhibition to GS even if the R1 position was non-optimal. For 
instance, 11 was 16-fold more potent than H23. Strikingly, the meta-hydroxyl group (R5) was 
critical to binding. Substitution of this hydroxyl groups with just hydrogen decreased potency 
significantly (16 versus 15 or 28 versus 27). SAR studies also indicated that substituents at the 
R7 position had an effect on activity in the following order of -CF3 > -H > -CH3 (15 or 13 versus 
11; 17 or 14 versus 12). In summary, analog development initiated from the substituted 
imidazole H23 led to a substituted pyrazole, namely 4-(4-(4-hydroxyphenyl)-3-(trifluoromethyl)-
1H-pyrazol-5-yl)pyrogallol (23) that had an in vitro IC50 value of 2.75 µM, an improvement in 
potency toward hGYS1 of more than 300-fold. 
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Kinetic characterization of compound 23
In order to understand the molecular features of our most potent analog, compound 23, we 
examined the kinetic characteristics of its interaction with GS (Figure 5A). Compound 23 has a 
competitive mode of inhibition for wild-type hGYS1, with a Ki value of 1.31 ± 0.14 µM (Figure 
5B). In light of the SAR and our kinetic results, we hypothesized that the binding of 23 to the 
active site of yGsy2p resembled the binding of H23 in the active site. In this model, the hydroxyl 
group at R1 position formed a hydrogen bond with the nitrogen backbone of Leu481. The three 
hydroxyl groups in the pyrogallol subunit formed hydrogen bonds with Thr514 or Glu517. 
Additional structural flexibility of hydrogen-bond formation depended on the relative position of 
23 in the binding pocket. As our SAR study showed, the hydroxyl group at R5 position was 
important to confer inhibition, and an additional hydrogen-bond formation between Arg320 and 
the pyrazole ring may also strengthen binding, particularly when an electron-withdrawing 
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trifluoromethyl group was present, and diminish binding when electron-donating methyl group 
was present in the same position in the pyrazole ring (Figure 5C). To validate whether 
compound 23 bound within the active site as modelled, we generated mutation within the active 
site where Y513 was mutated to L513. This mutation, Y513L, did not abolish GS activity. 
Unlike other active site mutations that almost completely eliminated enzyme activity, the Y513L 
mutant decreased GS catalytic activity by only 10-fold. Consistent with our modelled mode of 
binding, we found that inhibition by 23 toward Y513L was compromised compared to wild type 
(Figure 5D). 
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Figure 5. Kinetic characterization of 23. (A) Dose response curves for parent compound H23 
and the most potent analog 23 against wild-type hGYS1. (B) Michaelis-Menten curve of 
competitive inhibition for 23 versus UDPG. The values of goodness of fit (R2) are shown for all 
equations. 23 shows a Ki of 1.31 ± 0.14 µM under the tested condition. Ki value for 23 is the 
mean ± SEM from three independent experiments performed using duplicate measurements for 
each condition. (C) Hypothetical binding model of 23 to GS in the active site. The hydroxyl 
group at R1 position forms a hydrogen bond with the nitrogen backbone of Leu481. The three 
hydroxyl groups flanking the benzene form hydrogen bonds with Tyr514 or Glu517. An 
additional hydrogen bond is formed between Arg320 and the pyrazole ring, which is 
strengthened when electron-withdrawing group (like CF3) is present and diminished when 
electron-donating group (like CH3) is present. Manual docking of 23 in the active site was 
performed based on SAR and mode of inhibition studies. (D) Validation of 23 binding in the 
active site. Compound 23 showed decreased potency against the active-site mutant Y513L 
compared with wild-type yGsy2p. All IC50 curves represent one of three experiments performed 
using triplicate measurements for each condition, with mean ± SEM shown. 
Inhibition of glycogen synthase activity in cell lysates
We next examined these substituted pyrazoles as inhibitors of GS activity in cell lysates. 
Cultured cells normally do not accumulate large amounts of glycogen, largely due to the high 
levels of phosphorylation and the resulting low activity state of GS26. Lysates from two cell lines 
were prepared for GS activity measurement: the HEK293-PTG overexpressing PTG, a regulatory 
subunit of protein phosphatase 1, that recruits the phosphatase to glycogen where it promotes the 
dephosphorylation and activation of GS41,42, and glycogen accumulation; and the Rat-1 
fibroblasts which have low GS activity and glycogen as previously described43,44. The HEK293-
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PTG cells have a seven-fold increase in the GS activity ratio from 0.02 to 0.15. To determine GS 
activity in lysates and optimize the conditions for measurement, we measured the incorporation 
of 14C-glucose into glycogen at 0.2 mM UDPG and 1 mM G6P initially as a function of different 
lysate concentrations. We observed a linear increase in GS activity within the range of 0.075-1.5 
mg/ml lysate. Under the conditions of the assay, the lysate from the HEK293-PTG cells had 10-
fold more activity than the Rat-1 cell lysate (Figure 6A). To limit substrate utilization to under 
10%, we used 0.15 mg/mL HEK293-PTG lysate and 0.75 mg/mL Rat-1 lysate with imidazole 
H23, pyrrole 7 and pyrazoles 15, 19, 27 and 23. When tested at 100 μM, H23 and 7 did not 
significantly inhibit GS activity in lysates. However, the remaining four substituted pyrazoles, 
namely 15, 19, 27 and 23, reduced synthase activity in both HEK293-PTG and Rat-1 cell lysates 
by >30%. Consistent with its greatest potency toward purified enzyme, pyrazole 23 exhibited 
almost complete inhibition of synthase activity in lysates (Figure 6B). In summary, these 
analogs targeted GS activity in the context of the glycogen particles present in cellular lysates 
with potencies similar to those observed in purified enzyme preparations. 
Figure 6. Inhibition of glycogen synthase activity in cell lysates. (A) Synthase activity in 
HEK293-PTG and Rat-1 cell lysates in the presence of 0.2 mM UDPG and 1 mM G6P. The data 
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was fit to linear regression line with equations showing synthase activity rate (nmole/min, y-
value) under various lysate concentrations (mg/ml, x-value). The data represent averages of 
triplicate assays ± SEM. (B) Percent of 14C-glucose incorporation to control (DMSO) by cell 
lysates and recombinant hGYS1 in the presence of H23 and its analogs. For cell lysates and 
recombinant hGYS1, 100 μM and 20 μM compounds were used respectively. Averages of 
triplicate assays ± SEM are shown. 
DISCUSSION
The suppression of glycogen accumulation emerged as an attractive therapeutic approach for 
GSDs whose etiology derived from excessive glycogen storage. Animal models supported this 
approach in which genetic or chemical depletion of glycogen alleviated disease symptoms in 
models of Lafora disease27,28,29,30,45, Pompe disease31, and Cori disease32. Interestingly, recent 
studies suggested that type 2 diabetes (T2D) might also be within the GSD spectrum, as 
glycogen accumulation in pancreatic β cells under hyperglycemia contributed to the pathology of 
β-cell dysfunction16,17. 
Only a few studies identified molecules that targeted glycogen accumulation, including the 
widely-used glucose lowering T2D drug metformin46,47, mTORC1 inhibitor rapamycin that 
indirectly suppress GS activity through signaling regulation31, GYS2 RNAi that mediates 
enzyme reduction32, and the newly developed antibody-enzyme fusion that can degrade 
polyglucosan45. However, these molecules either targeted glycogen synthesis in an indirect 
manner, or present a challenge for the delivery of therapeutics to the central nervous system. In 
this study, we adapted a high-throughput fluorescence polarization assay to screen directly for 
small-molecule modulators of GS. A HTS of a commercial 50K chemical library identified 117 
primary hits against yGsy2p, and through 14C-glucose incorporation assay only 1 hit was 
Page 26 of 48
ACS Paragon Plus Environment






























































validated as hGYS1 inhibitor (Figure 2). The low translation between these two assays might lie 
in the nature of these two systems, since fluorescence polarization assay is affinity-based 
whereas the radiochemical assay is activity-based. In addition, the kinetic aspects of the two 
enzyme systems differ as the impact of regulatory input on the enzyme results in different 
outcomes where regulation of yeast GS by G6P primarily impacts kcat, whereas in mammalian 
systems the impact is primarily on Km for substrate48,49. There is no evidence that the kinetic 
steps in catalysis differ between the two enzymes, but it is clear that the manner in which the 
rates for those individual steps are impacted by regulatory input does differ. A more sensitive 
assay directly targeting hGYS1 is likely to offer better screening outcome. Nonetheless, our FP 
assay provided a novel HTS assay as a starting point, and did indeed identify a competitive 
inhibitor of UDPG, namely (rac)-2-methoxy-4-(1-(2-(1-methylpyrrolidin-2-yl)ethyl)-4-phenyl-
1H-imidazol-5-yl)phenol (H23), that bound within the active site of yeast yGsy2p. This outcome 
was supported by both an X-ray structure and by kinetic studies using H23 and analogs 
developed in a subsequent SAR study. The site of interaction was surprising because the assay 
identified small-molecule inhibitors that displaced G6P binding. However, a close inspection of 
the known, eukaryotic GS structures demonstrated that the UDPG and G6P binding sites resided 
on opposing ends of the same alpha-helix, with Tyr492 stacked against the uracil ring of UDP 
and His500 forming a hydrogen bond with the phosphate moiety of G6P (Supplemental Figure 
3). Considering this structural proximity and the cooperative nature of the structural transitions in 
GS, it was not surprising that binding at one site could transmit structural information to the 
other site and that under the subsaturating conditions of our HTS assay, binding of compounds 
within the active site could promote displacement of the fluorophore from the G6P site. 
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Humans have two isoforms of GS, namely hGYS1 and hGYS2. The fact that hGYS1 is 
universally expressed in most tissues while hGYS2 is restrictively expressed in liver prompted us 
to identify inhibitors against hGYS1 in the hope of diminishing brain glycogen stores, aberrantly 
accumulated in some GSDs such as Lafora disease26. The high sequence homology between 
hGYS1 and hGYS2 enzymes could make it difficult to develop isoform-specific inhibitors. 
Nonetheless, inhibition of hGYS2 might aid in the therapeutic efficacy of GSDs with excessive 
glycogen accumulation in liver that would ultimately lead to liver damage. Recently, Pursell et 
al. showed that GYS2 inhibition with RNAi prevents liver injury in mouse models of Cori 
disease and had no adverse effects32. 
Mutations in GYS150 or GYS251 in rare GSDs lead to decreased glycogen in muscle and liver 
respectively. Disruption of the mouse GYS1 gene resulted in 90% perinatal lethality, likely due 
to cardiac developmental problems during embryogenesis, but the surviving mice were 
ostensibly normal and lived normal lifetimes52. Disruption of GYS2 in mice largely mimicked 
the phenotype of human GSD0 patients, namely tendencies to post-prandial hyperglycemia and 
to hypoglycemia upon fasting but compatible with a relatively normal life51,53. Given that small-
molecule inhibition will not have the penetrance of genetic defects, inhibition of GS activity by 
small-molecules is unlikely to elicit extreme phenotypes, and small-molecule inhibition remains 
as a potentially valuable means of treating these devastating diseases. 
CONCLUSIONS
In summary, this study described a strategy for developing a high-throughput FP assay for the 
screening of small-molecule inhibitors of GS, the binding mode of a leading imidazole H23 
validated through both X-ray crystallographic and kinetic data; and an SAR study leading to 
analogs, such as pyrazole 23, with low micromolar potency. These outcomes suggest that 
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targeting glycogen synthase with small-molecule inhibitors represents an attractive approach for 
developing new therapeutics for diseases in the GSD family. Unlike other enzyme-based 
strategies where complete inhibition is the ultimate objective, a partial reduction of GS activity 
may be sufficient to alleviate unwanted and damaging levels of glycogen deposition in the neural 
tissue of patients suffering from Lafora disease27,28,30. The challenges of developing any 
therapeutic, nevertheless, remain the same, and the gulf that stretches between our identification 
of a pyrazole inhibitor 23 with activity in the low micromolar range and a therapeutic candidate 
is wide and deep. Initial efforts will involve microsomal studies to evaluate anticipated 
pharmacokinetic concerns about unwanted redox reactions of pyrazole 23 to 4-(4H-pyrazol-4-
ylidene)- or 2,3-dihydroxy-4-(3H-pyrazol-3-ylidene)cyclohexa-2,5-dien-1-ones. We will use a 
combination of synthesis (i.e., SAR studies) and computational modeling to identify analogs that 
avoid this concern and retain desired physiochemical properties (i.e., water solubility; 
bioavailability); we will evaluate any promising, new leading structures for potential toxicity 
issues (e.g., hERG studies); and we will explore biotinylated analogs to confirm the specificity of 
these pyrazole analogs for the desired target. These initial, encouraging results bode well for the 
future development of small-molecule strategies to study and potentially treat GSDs.
EXPERIMENTAL SECTION
Materials
The 50K compound Diversity set library, the primary hits H1-H110, and analogs 1-4, 7-9 were 
purchased from ChemBridge Corporation (San Diego, CA). Analogs 5, 6 and 10 were purchased 
from Vitas-M Laboratory (Champaign, IL). The purity of these purchased compounds were >
95% based on the spectra (either LC/MS or NMR) provided by the vendors. All pyrazoles were 
characterized and validated by both LC/MS and NMR analyses. 
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Synthesis and purification of GlcN6P-fluorescein-5-Ex 
The tracer was synthesized by using a standard coupling reaction between an amine and N-
hydroxysuccinimidyl (NHS) ester. The reaction included: 100 mM NaHCO3 (pH 8.4), 130 mM 
glucosamine-6-phosphate (GlcN6P) pH 8.0, 41.6% DMSO and 14 mM fluorescein-Ex, 
succinimidyl ester. The reaction was incubated for 1 hour at 37°C followed by an overnight 
incubation at 25ºC with continuous stirring, the reaction was stopped by addition of Tris-HCl 
(pH 8.0) to a final concentration of 0.2 M. Purification of GlcN6P-fluorescein-5-Ex was carried 
out by HPLC on a semi-preparative Luna C18 column (250×10 mm, 5 μm) from Phenomenex. 
The eluents used were 25 mM NH4OAc (pH 5.5) (E1) and 100% methanol (E2). Elution was 
performed by the following gradient: T0= 5% (v/v) E2, T10= 50% (v/v) E2, T30= 50% (v/v) E2, 
T45= 75% (v/v) E2, T55= 5% (v/v) E2 at a flow rate of 4 mL/min. The fractions containing the 
UV-containing fractions were collected, dried using a SpeedVac, dissolved in water and stored at 
-20ºC. The fractions containing GlcN6P-fluorescein-5-Ex were identified and confirmed by mass
spectrometric analysis. The final tracer concentration was determined by UV spectroscopy 
(Abs492~9.2 × 104 M−1 cm−1).
Fluorescence polarization assay
All the fluorescence polarization (FP) experiments were performed on an EnVision multimode 
plate reader (Perkin Elmer) with the λex= 485 nm and λem= 535 nm. The FP experiments were 
performed in 384-well, black, flat bottom microplates at 25ºC. After addition of all reagents, 
plates were spun down for a minute at 1000g in a centrifuge followed by measurement of the FP 
signals, where each well was flashed 10 times and the average values were used. All polarization 
values were expressed as milli-Polarization units (mP), calculated from equation 1:
(1)𝑚𝑃 = (1000) ∗
𝑆 ― 𝐺 ∗ 𝑃
𝑆 + 𝐺 ∗ 𝑃    
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Where: S= fluorescence intensity measured when the excitation and emission polarizers are 
parallel and P= fluorescence intensity measured when the excitation and emission are 
perpendicular and G= grating factor that corrects for instrument bias. All the nonlinear regression 
analyses were performed by fitting the experimental data to the defined equations using 
SigmaPlot version 13.0.
Determination of the GlcN6P-fluorescein-5-Ex/yGsy2p equilibrium dissociation constant 
The concentration of the tracer was initially varied from 0-100 nM in order to determine the 
optimal assay concentration. Based on total fluorescence intensity and mP values, the optimal 
concentration was determined to lie between 10-40 nM in the final assay. The binding affinity 
for the tracer for yGsy2p was determined by adding the tracer to a final concentration of 20 nM 
to each well in the presence of varying yGsy2p concentrations (0 to 50 µM) in a final volume of 
50 µL. The final assay buffer consisted of 15 mM Tris-HCl (pH 7.8) and 15 mM NaCl, the plate 
was incubated at 25ºC for 10 minutes before reading. The dissociation constant, i.e. Kd was 
calculated by fitting the experimental data to equation 2:
                                                                                                 (2)𝑓 = 𝑦0 +
𝑎 ∗ 𝑥
𝑏 + 𝑥
Where =mP, y0=mPmin, a= mPmax-mPmin, b= Kd and = Concentration of yGsy2p. Experiments 𝑓 𝑥
were performed in triplicate.
Activation of yGsy2p or hGYS1 in the presence of G6P or GlcN6P
The activation of hGYS1 or yGsy2p in the presence of G6P or GlcN6P was determined using the 
radiochemical assay previously described33 and the data was fit to equation 2. However, the 
parameters were defined as: = % activation, y0 = % activationmin, a=% activationmax - % 𝑓
activationmin, = Concentration of G6P or GlcN6P and b= AC50. Experiments were performed in 𝑥
triplicate.
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G6P was serially diluted in 15 mM Tris-HCl (pH 7.8) to provide a final concentration ranging 
from 0.68 µM to 40 mM. The reaction mixture contained a final concentration of 15 mM Tris-
HCl (pH 7.8), 15 mM NaCl, 20 nM GlcN6P-fluorescein-5-Ex, 4.2 µM yGsy2p and varying 
concentrations of G6P in a final volume of 50 µL. The plate was incubated for 10 minutes at 
25ºC before reading. The Kd was determined by fitting the observed mP changes to equation 3: 
                           (3)𝑓1 = mP𝑚𝑖𝑛 +
(mP𝑚𝑎𝑥 ― mP𝑚𝑖𝑛)
(1 + 𝑥𝐸𝐶50)^( ― 𝐻𝑖𝑙𝑙𝑠𝑙𝑜𝑝𝑒)
Where 1= mP, EC50= Kd, = Concentration of G6P. Experiments were performed in triplicate.𝑓 𝑥
Determination of Z′-factor
To determine the quality of the FP-displacement assay for adaptation for HTS, the Z′-factor was 
calculated using equation 4:
(4)𝑍′ = 1 ―
3(𝜎𝑝 + 𝜎𝑛)
|𝜇𝑝 ― 𝜇𝑛|                                                                     
where σp and σn are the standard deviations of the signal for the positive and negative controls.
For the negative control 2 µL of H2O was added and for the positive control 2 µL of G6P was 
added to a final concentration of 2 mM in a 384-well plate. The protein sample was prepared in 
25 mM Tris-HCl (pH 7.8), 25 mM NaCl, 7 µM yGsy2p, 40 nM tracer and dispensed by a Multi-
drop 384 liquid dispenser (Titertek) into the wells with either H2O or G6P. The plate was spun 
down in a centrifuge followed by measurement of the FP signals.
Expression and purification of yGsy2p and hGYS1
The His-tagged yGsy2p recombinant enzyme was expressed in BL21 (DE3) Escherichia coli and 
purified using a two-step procedure including affinity chromatography on Ni2+-nitrilotriacetic 
acid-agarose and ion exchange purification on Q-sepharose column10. The hGYS1 in the pFL 
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vector38 was modified by deleting the intein-chitin binding domain fusion at the C-terminus and 
replacing it with a simple non-cleavable 6 His-tag at the C-terminus. Purification of the ×
construct was achieved using Ni-NTA resin (Qiagen product #31314) following manufacturer’s 
instructions. Separately, a construct of hGYS1 was generated in which the C-terminus was 
truncated at position 634 and the N-terminal phosphorylation sites at positions 8 and 11 were 
simultaneously mutated to Asn residues, that avoids solubility issues associated with mutation of 
these residues to Ala, in order to generate the hGYS1634S8,11N construct. This construct was 
also fused to the same C-terminal 6 His-tag for purification using Ni-NTA resin.×
Determination of kinetic parameters
Enzyme activity of GS was determined using UDPG as a substrate through 14C-glucose 
incorporation assay by monitoring the amount of radiolabeled glucose being incorporated into 
glycogen33. Unless otherwise noted, yGsy2p activity was measured in reaction solution 
containing 0.3 mM UDPG in the absence or presence of 0.04 mM G6P. The activity of mutant 
hGYS1634S8,11N enzyme was measured using 0.2 mM UDPG and 0.4 mM G6P, while the 
activity of wild-type hGYS1 was measured using 0.2 mM UDPG and 1 mM G6P. All kinetic 
data analyses were performed using the program package SigmaPlot (version 13.0) by fitting the 
data to the appropriate kinetic equation. The IC50 curves for H23 and its analogs were fit to the 
four parameter logistic equation. Titration experiments for Michaelis–Menten curves were 
performed by covarying inhibitor and substrate concentrations. The reaction mixture contained 5 
μg/ml yGsy2p, varied UDPG (0.2-8 mM in the absence or presence of 7.2 mM G6P) and H23 
concentrations (0-0.8 mM). All data were fit to competitive, non-competitive and uncompetitive 
inhibition models in SigmaPlot (Version 13.0). Appropriate model was selected through analysis 
of goodness-of-fit and the residuals of those fits. All experiments include the controls contained 
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2% (v/v) DMSO. The values presented here are the averages ± the standard errors of the mean of 
three independent experiments with duplicate measurements for each data point in each 
experiment.
Crystallization and structure determination
Yeast Gsy2p crystals were obtained using hanging drop vapor diffusion method10. Briefly, the 
protein solution was prepared at 3 mg/ml containing 25 mM G6P. The protein solution was 
mixed with crystallization reservoir solution containing 0.1 M Bis-Tris, pH 5.9 and 13-15% 
PEG300. The crystals were soaked with compounds (0.5 mM) on sitting drop plates to obtain 
inhibitor-bound yGsy2p complex. The crystals were cryo-protected and frozen. Diffraction data 
sets were collected using X-ray crystallography at the Advanced Photon Source at beamline 19-
ID, operated by the Structural Biology Center at Argonne National Laboratory. The data sets 
were then indexed, integrated and scaled using the HKL3000 program package. The structures 
were solved by molecular replacement using MOLREP, as implemented in the Collaborative 
Computational Project Number 4 (CCP4) program suite. The G6P bound yGsy2p-R589/592A2 
mutant structure (pdb code: 3NB0) was used as the model for molecular replacement. The 
structures were initially refined with a single round of rigid body refinement for individual 
domains, followed by iterative rounds of restrained refinement with the application of domain-
based TLS and NCS restraints using REFMAC5 as implemented in CCP4. COOT (version 
0.7.2.1) was used to visually inspect and manually adjust the refined models.
Compound synthesis
Synthesis of pyrazoles 11-30 was performed in a 3-step procedures which include 1) synthesis of 
polyhydroxydeoxybenzoins; 2) ring-closure reaction for the synthesis of isoflavones with or 
without de-acetylation of phenolic groups; and 3) recyclization reaction of chromones under 
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hydrazine actions (Scheme 1). Initial Hoesch reaction of substituted polyphenols and 
arylacetonitriles in boron trifluoride etherate with passing of anhydrous HCl led to formation of 
A-ring polyhydroxylated deoxybenzoins I2-1 – I2-5 and I2-9 – I2-1254. Alternative condensation
of pyrrogallol or 4-flouroresorcinol with phenylacetic acids in boron trifluoride etherate at 
heating was performed for the synthesis of 4’-hydroxy- or 4’-cyano deoxybenzoins I2-6 – I2-855. 
Ring-closure reaction with Vilsmeier reagent or trifluoroacetic anhydride in pyridine after work-
up with water afford 2-unsubstituted or 2-trifloromethyl isoflavones. Synthesis of 2-methyl 
isoflavones I3-1, I3-2, I3-8, and I3-19 was performed by reaction of polyhydroxydeoxybenzoins 
with acetic anhydride in presence of potassium acetate with the following deacylation in ethanol 
without purification of intermediate acetates. Target pyrazoles 11-30 were synthesized by the 
reaction of synthesized 2 (un)substituted isoflavones I3-1 – I3-20 with hydrazine hydrate in 
ethanol under reflux. 
Analysis of GS activity from cell lysates
HEK293-PTG cells were generated by transfecting HEK293 cells56 with the plasmid pCDH-
FLAG-PTG, harboring the mouse PTG coding region and the hygromycin antibiotic resistance 
gene utilizing Lipofectamine following manufacturer specifications. Mixed clones were selected 
for ~10 days in the presence of 0.2 mg/mL hygromycin, expanded and stored in liquid N2. 
Analyses of protein expression, GS activity ratio in the absence and presence of saturating 
concentrations of UDPG (4.4 mM) and of G6P (7.2 mM) and glycogen levels indicated that the 
protein was expressed, the GS activity ratio was increased 7-fold, from 0.02 in control cells to 
0.15 in transfected cells, and that glycogen was increased by 90-fold. Quantitation of the 
expression of PTG is difficult because the basal levels are very low, undetectable under our 
conditions. 
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For lysate preparation the HEK293-PTG cells were cultured in 100 mm plate with 5.5 mM 
αMEM, 10% FBS, 6 μg/mL penicillin, 10 μg/mL streptomycin, and 0.2 mg/ml hygromycin. Rat-
1 cells were cultured in 100 mm plate with 25 mM DMEM, 10% FBS, 6 μg/mL penicillin and 10 
μg/mL streptomycin. Cells were grown for 3-4 days till confluency. Before harvest, cells were 
washed twice with 5 mL ice-cold GS buffer (50 mM Tris-HCl pH 7.8, 20 mM EDTA, 25 mM 
KF). Then 400 μL GS homogenization buffer (50 mM Tris-HCl pH 7.8, 10 mM EDTA, 2 mM 
EGTA, 100 mM NaF) with protease inhibitor (0.1 mM TLCK, 10 μg/ml leupeptin, 1 mM 
benzamidine, 0.5 mM PMSF, 1 mM Na3VO4) and β-mercaptoethanol (0.4%) plus Triton 100 ×
(0.2%) were added to each 100 mm plate. Plates were frozen on liquid N2 and scraped. Then 
lysates were transferred to 2 ml Eppendorf tube, sonicated for 15 seconds twice on ice, and 
placed on nutator for 10 minutes at 4 ºC. Protein concentrations were measured using the 
Bradford reagent and indicated that the protein concentration was the same in both lysates. GS 
activity was initially measured with varying concentration of the lysates. For monitoring the 
effect of small-molecules on GS, HEK293-PTG cell lysates were diluted 10-fold while Rat-1 cell 
lysates were diluted 2-fold in homogenization buffer to achieve steady-state kinetics under the 
conditions we used in 14C-glucose incorporation assay33. GS activity in cell lysates was measured 
in 50 mM Tris-HCl buffer at pH 7.8 with 6.7 mg/ml glycogen, and subsaturating concentrations 
of UDPG  (0.2 mM) and G6P (1 mM) in the absence or presence of 100 μM H23 and its analogs. 
All assays including the controls contained 2% (v/v) DMSO.
Generation of yGsy2p Y513L mutant
To characterize the binding pattern of compound 23, active site mutation Y513L was made 
without necessarily compensating enzyme activity. Point mutation of Y513L was performed 
using QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies) in the  pET-28A 
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harboring the yeast Gsy2p cDNA49 using forward primer 5′-
CTACGAGCCTTGGGGTCTCACACCTGCAGAATGTAC-3′ and its complement primer, and 
was confirmed by DNA sequencing. The mutant protein was purified exactly the same way as 
was yGsy2p. However, the yield was significantly less compared to WT protein. Additionally, 
the activity of Y513L mutant is around 10-fold lower than WT enzyme. Kinetics experiments 
with Y513 mutant were performed under saturating G6P concentration (7.2 mM).   
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GSD: glycogen storage disorder; GS: glycogen synthase; yGsy2: yeast glycogen synthase 2; 
hGYS1: human glycogen synthase 1; SAR: structure-activity relationship; GlcN6P: 
glucosamine-6-phosphate; G6P: glucose-6-phosphate; PTG: protein-targeting-to-glycogen; HTS: 
high-throughput screening; UDPG: Uridine diphosphate glucose; FP: fluorescence polarization.
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